---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-000008"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2025-01-02T23:59:59+00:00"
generated_at: "2026-05-28T18:18:14.627873+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Immunocore appoints Travis Coy as EVP, CFO, Head of Corporate Development effective Jan 1, 2025

## Summary
- Annual base salary $500,000; target cash bonus 40% of salary; sign-on bonus $200,000 in three installments.
- Grant of 274,033 options under 2021 Equity Incentive Plan, vesting over 4 years (25% at 1-year anniversary, then quarterly).
- Mr. Coy brings over 20 years at Eli Lilly, most recently VP, Head of Transactions and M&A.
- Severance: 18 months base salary plus 150% target bonus if terminated without cause within 18 months of change of control; 12 months base otherwise.

## SEC filing metadata
- accession: 0001140361-25-000008
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2025-01-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036125000008/0001140361-25-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036125000008/ef20040795_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-000008
- JSON: https://secwatch.observer/filing/0001140361-25-000008.json
- Plain text: https://secwatch.observer/filing/0001140361-25-000008.txt

## Key facts
- Executive change
  Travis Coy resigned as Director at Immunocore Holdings plc.
  - Action: resigned
  - Role: Director
  source text: In connection with his entry into the Employment Agreement, Mr. Coy resigned from the Company’s board of directors (the “Board”), effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671927/000114036125000008/0001140361-25-000008-index.htm
- Executive change
  Travis Coy was appointed as Executive Vice President, Chief Financial Officer and Head of Corporate Development at Immunocore Holdings plc.
  - Action: appointed
  - Role: Executive Vice President, Chief Financial Officer and Head of Corporate Development
  source text: On December 31, 2024, Immunocore LLC, an indirect, wholly owned subsidiary of Immunocore Holdings plc (“Parent” and, together with Immunocore LLC, the “Company”), entered into an employment agreement (the “Employment Agreement”) with Travis Coy, pursuant to which Mr. Coy will serve as the Company’s Executive Vice President, Chief Financial Officer and Head of Corporate Development as well as the Company’s principal financial officer, effective as of January 1, 2025 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671927/000114036125000008/0001140361-25-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.